
Olezarsen, a novel antisense therapy, significantly reduced triglycerides by approximately 50% compared to placebo in patients with moderate to severe hypertriglyceridemia, with a favorable safety profile.


coremsg

A drug targeting mRNA essential for APO C-III production provided a 50% reduction in triglycerides in BRIDGE-TIMI 73a, the largest ever observed in a controlled trial.

Early Olezarsen Results Show 50% Reduction in Triglycerides

novel-antisense-therapy-olezarsen-demonstrates-significant-triglyceride-reduction-in-phase-2b-trial


Novel Antisense Therapy Olezarsen Demonstrates Significant Triglyceride Reduction in Phase 2b Trial
